62 results about "Topical drug" patented technology

The invention discloses a renal artery balloon catheter for local drug perfusion, and relates to the technical field of renal artery balloon catheters, the renal artery balloon catheter comprises an access unit, and the access unit comprises a connecting end, a perfusion joint arranged at one end of the connecting end, and a liquid injection joint arranged on the outer wall of the connecting end. The balloon has the advantages that a traditional integrally-injection-molded balloon is changed to be composed of multiple independent tubes, the balloon can be matched with the renal artery with the larger bending degree, the production cost of an enterprise can be reduced, the corrugated balloon formed through expansion and the concave-convex surface can disperse contact pressure, local compression on the intima is reduced, and the balloon has the good sealing effect. And the'grooves' of the waveform structure are in multi-point contact with the blood vessel wall, so that the friction force is increased, and the balloon is prevented from sliding under the impact of blood flow.

The present invention relates to multiple polypeptides with high safety, cell repair capacity, and anti-inflammatory, hydrating and moisturizing effects, and the use thereof in cosmetics, wherein the amino acid sequences of the polypeptides are as set forth in SEQ ID NO: 1-SEQ ID NO: 6. The present invention also relates to a polynucleotide encoding the polypeptides, wherein the sequence of the polynucleotide is as set forth in SEQ ID NO: 7-SEQ ID NO: 12, and the sequence of the polynucleotide can be used for the detection of Deinococcus weizhi. In addition, further provided is a topical drug or a cosmetic, which contains any one of the polypeptides or a combination thereof as an active ingredient.

Provided herein are methods for treating skin-related diseases or disorders (e.g., melasma). Also provided are pharmaceutical compositions of midostaurin or a pharmaceutically acceptable salt thereof formulated for topical administration. Also described are methods for preparing such topical pharmaceutical compositions and methods for using the topical pharmaceutical compositions to treat a subject.

The invention relates to an external traditional Chinese medicine preparation for preventing and treating HPV (human papillomavirus) infection, which belongs to the technical field of external medicines and comprises the following raw materials: 1-10 parts of gallnut, 1-10 parts of szechwan chinaberry fruit, 1-10 parts of golden cypress, 1-10 parts of fructus cnidii, 1-10 parts of radix sophorae flavescentis, 1-10 parts of cyrtomium rhizome, 1-10 parts of rhizoma atractylodis, 1-10 parts of cortex dictamni, 0-10 parts of calomel, 0-10 parts of cinnabar and 0-10 parts of borneol. The external traditional Chinese medicine preparation disclosed by the invention is locally administrated through the vagina, so that the active ingredients directly reach the focus, and the external traditional Chinese medicine preparation is safe and convenient, and is suitable for resisting HPV infection, cervicitis, cervical erosion, pelvic inflammation, bacterial vaginitis, trichomonas vaginitis, mixed vaginitis, peculiar smell of private parts, pruritus of private parts, dryness of private parts, abnormal leucorrhea and pruritus and causalgia of vulva.

A graduated dose dispenser and applicator for topical medications wherein medications may be dispensed in an accurate and safe manner. The graduated dose dispenser and applicator utilizes a body, plunger, screw rod, pin, knob, channel, plunger lip, detent, alignment ribs, and rounded applicator tip to accurately dispense and apply topical medications.

The invention belongs to the field of biological medicine, and particularly relates to lipid nanoparticles for local drug delivery, a preparation method of the lipid nanoparticles and application of the lipid nanoparticles to preparation of anti-scar drugs. The lipid nanoparticle comprises a lipid carrier and nucleic acid wrapped by the lipid carrier, and the lipid carrier comprises the following components: an ionizable lipid, a permanent cationic lipid, a pegylated lipid, an auxiliary phospholipid and a sterol compound; the molar ratio of the ionizable lipid to the permanent cationic lipid to the pegylated lipid to the auxiliary phospholipid to the sterol compound is (25-45): (5-25): (1-2): (5-15): (35-40). In order to solve the problem of single administration of lipid nanoparticles in the prior art, the lipid nanoparticles are designed to be externally applied and applied for local administration through proportion regulation and control, so that the targeting property is improved, and the administration concentration is increased. Whole-body blood circulation is avoided, and toxic and side effects and off-target performance are reduced. Therefore, the dual purposes of synergism and toxicity reduction are achieved.

The present invention discloses a fiber membrane that promotes the healing of infected wounds, a preparation method and an application thereof. The fiber membrane includes a plurality of non-randomly arranged spinning nanofibers, which are prepared by electrostatic spinning from a material including L-polylactic acid. The porous microstructure of the fiber membrane of the present invention provides a suitable microenvironment for cell migration and epithelial regeneration, and can promote the healing of bacterial-infected wounds. It has been verified that the fiber membrane of the present invention can effectively promote wound healing through antibacterial, relieving inflammation, collagen regeneration and angiogenesis. In addition, the present invention can maximize the antibacterial and tissue repair functions without adding external drugs through ultrasound enhanced treatment, and has broad application prospects.

The invention provides miconazole nitrate emulsifiable paste and a preparation process, and belongs to the technical field of external medicines, and the miconazole nitrate emulsifiable paste is characterized by comprising the following components in parts by mass: 1.8-2.0 wt% of miconazole nitrate, 0.3-2.0 wt% of an allantoin eugenol amide ester penetration enhancer, 3-5 wt% of medium-chain triglyceride, 5-10 wt% of glycerin monostearate, 8-15 wt% of white vaseline, 6-12 wt% of glycerol and the balance of water. The cleaning agent is prepared from, by weight, 0.01%-0.10% of bis (hydroxymethyl) imidazolidinyl urea, 6%-12% of octadecanol, 1%-3% of triethanolamine and the balance purified water. The preparation process comprises the steps of preparation of cream, homogenization of miconazole nitrate emulsion and preparation of the miconazole nitrate cream. According to the invention, the nanoscale miconazole nitrate cream product with uniform and fine texture is prepared from the aspects of drug particle size optimization and homogenization; the added allantoin eugenol amide ester penetration enhancer is safe and non-irritant, and when the allantoin eugenol amide ester penetration enhancer and miconazole nitrate are used together, penetration of the ointment is promoted, and skin recovery is accelerated; meanwhile, the problems of yellowing, deterioration and the like of the cream can be effectively prevented.

For minoxidil in a minoxidil-containing formulation to be efficiently absorbed through the scalp, it is important that the formulation blends well with and spreads across the surface of the scalp. In other words, the object of the present invention is to provide a minoxidil-containing topical pharmaceutical composition that blends well with the skin. [Solution] (a) 5-15 w / v% minoxidil, (b) at least one selected from the group consisting of cetylpyridinium and its salts, and benzethonium and its salts, and (c) 8-30 w / v% water, (d) lower alcohol, and (e) 10-30 w / v% polyhydric alcohol. A topical pharmaceutical composition characterized in that the polyhydric alcohol is at least one selected from the group consisting of 1,3-butylene glycol, dipropylene glycol, propylene glycol, glycerin, and polyethylene glycol.

The utility model belongs to the technical field of urethral stents, in particular to a urethral stent with a medicine guide structure, which comprises a urethral stent main body and a shunting groove, the shunting groove is arranged in the urethral stent main body, an annular groove is arranged on one side of the urethral stent main body close to the shunting groove, and the shunting groove is communicated with the annular groove. According to the urethral stent with the medicine guiding structure, after the urethral stent is inserted into the urethra, the urethra is kept unobstructed, when the urethral stent is inserted into the urethra and medicine needs to be applied, the butt joint pipe is rotated, the first thin film is punctured by the puncture needle, the liquid medicine bag is extruded to deform, and liquid medicine in the liquid medicine bag is guided to the urethra wall through the diversion groove; when the liquid medicine in the liquid medicine bag is used up, an injection needle tube and the like are used for puncturing the second film to inject the liquid medicine, the injected liquid medicine is in contact with the urethra wall through the diversion groove, and the urethra support is inserted into the urethra to facilitate local medicine application.

This invention relates to topical drug delivery formulations, formulated to carry at least one drug, be applied to an open wound, and enable systemic absorption of the at least one drug via the open wound to provide a systemic therapeutic effect for a predetermined period of time. In some embodiments, the invention concerns a topical drug delivery composition comprising a rapid onset local anaesthetic agent and / or an analgesic agent, and a drug delivery formulation, for providing both local and systemic anaesthesia and / or analgesia.

The invention provides hydrogel for treating atopic dermatitis and application thereof, and relates to the technical field of biomedicine, and the hydrogel comprises SA, plasma water, L-G2 and / or FLA. Through in-vitro cytotoxicity tests and antibacterial performance tests, preliminary evaluation is carried out on the hydrogel, it is proved that the hydrogel can inhibit staphylococcus aureus and escherichia coli, meanwhile, the hydrogel shows low cytotoxicity, and the basic requirements of biomedical dressing are met. In animal experiments, by comparing skin lesion conditions before and after AD mouse treatment, it is observed that the hydrogel can significantly improve back skin lesion of a mouse and has a good anti-inflammatory effect. Pathohistological analysis shows that the hydrogel can reduce the thickness of epidermis, inhibit the increase of the TNF-alpha level induced by DNCB and promote inflammation relief. Meanwhile, SA can provide a wet healing environment for skin wounds and is beneficial to promoting wound repair. Therefore, the hydrogel provides a new strategy for AD treatment and management, and is expected to become a novel external medicine for AD treatment.

The invention discloses artificial saliva and a preparation method of artificial saliva hydrogel. The artificial saliva is prepared from the following raw materials in parts by mass: 0.5 to 1 g of KCl, 0.2 to 0.4 g of K2HPO4, 0.2 to 0.8 g of NaCl, 0.2 to 0.4 g of KH2P O4, 10.04 to 20.8 g of CaCl2, 1.5 to 3 g of Nacaboxymethlecellulose, 60 to 120 mg of brown moss alcohol, 495 to 1000 ml of natural coconut juice and 5 to 10 ml of herba sarcandrae extract. By selecting the glabrous sarcandra herb extract, anti-inflammatory and anti-tumor treatment is realized, so that the traditional Chinese medicine composition has a remarkable effect on dry mouth caused by radiotherapy; through the form of a gel bead preparation, the beverage is more portable and unique in taste. The gel beads serve as one of oral local administration preparations, and after the gel beads are exploded, drugs can target small glands which are located below oral mucosa and secrete saliva, and the rapid drug effect is achieved. Direct local administration to the oral mucosa may provide rapid drug action, activate small salivary glands within the buccal mucosa, while avoiding systemic drug exposure and off-target effect.

The invention discloses a periodontal brace for treating periodontitis in Uyghur medicine, and relates to the technical field of auxiliary devices for dental treatment. The tooth socket comprises a customized half-soft membrane tooth socket body, and a medicine storage groove is formed in the inner side of the tooth socket body corresponding to the periphery of gingiva and used for containing Uyghur medicine ointment. The tooth socket is ensured to be fit with the shape of the oral cavity through mold taking customization, the medicine storage groove can prolong the contact time of medicine and periodontium, the medicine storage groove is matched with pure natural Uyghur medicine to avoid the side effect of chemical medicine, and the tooth socket can be repeatedly used. The problems that an existing local treatment medicine is short in treatment effect and obvious in side effect are solved, the treatment effect and safety of chronic periodontitis are improved, and the traditional Chinese medicine composition is suitable for clinical periodontitis local medicine treatment scenes.

The invention relates to the technical field of preparation of liquid medicine for treating corn, in particular to a preparation method of liquid medicine for treating corn. The technical problems that in the prior art, side effects on the human body are large, the nursing difficulty is high, and scars are likely to be formed are solved through the preparation method of the medicine liquid for treating the corn. According to the technical scheme, the preparation method of the liquid medicine for treating the corn comprises the following steps: step 1, sequentially weighing sodium chloride, magnesium chloride, salt, vinegar and brine according to the required weight; 2, fully stirring to completely dissolve sodium chloride, magnesium chloride and salt in the brine, and then adding the rest brine and vinegar; 3, boiling with big fire, and continuing to boil with small fire; all components used for preparing the liquid medicine do not contain hormones, no burden is brought to the skin when the liquid medicine is used for treating the corn, adverse symptoms such as local skin dryness and sensitivity caused by external medicines are avoided, nausea and dizziness are not caused, and the liquid medicine has no damage to the skin of an affected part.

This invention provides a hydrogel for treating atopic dermatitis and its applications, relating to the field of biomedical technology. The hydrogel comprises SA, plasma water, L-G2, and / or FLA. Preliminary evaluation of the hydrogel was conducted through in vitro cytotoxicity and antibacterial performance tests, confirming its ability to inhibit Staphylococcus aureus and Escherichia coli. Simultaneously, the hydrogel exhibits low cytotoxicity, meeting the basic requirements for biomedical dressings. In animal experiments, by comparing skin lesions before and after treatment in AD mice, the hydrogel was observed to significantly improve skin lesions on the back of mice, demonstrating good anti-inflammatory effects. Pathological histological analysis showed that the hydrogel can reduce epidermal thickness, inhibit the increase in TNF-α levels induced by DNCB, and promote inflammation relief. Simultaneously, SA can provide a moist healing environment for skin wounds, helping to promote wound repair. Therefore, this hydrogel provides a new strategy for the treatment and management of AD and is expected to become a novel topical drug for AD treatment.

This invention belongs to the field of traditional Chinese medicine technology, and relates to a topical Chinese medicine composition, topical drug, topical patch, acupoint patch, and preparation method and application for treating nausea and vomiting caused by chemotherapy for intracranial tumors. The Chinese medicine composition consists of the following raw materials in parts by weight: 1-2 parts of Ligusticum chuanxiong, 1-2 parts of Gastrodia elata, 2-4 parts of Uncaria rhynchophylla, 1-2 parts of Citrus aurantium, 1-2 parts of Sinapis alba, 1-2 parts of Clematis chinensis, 0.5-1 part of Melia toosendan, 0.5-1 part of Panax ginseng, 1-2 parts of Pinellia ternata, 1-2 parts of Albizia julibrissin bark, 0.5-1 part of Lentinus edodes, and 1-2 parts of Astragalus membranaceus. This Chinese medicine composition has the effects of relieving nausea and vomiting, soothing the liver and strengthening the spleen, detoxifying and eliminating turbidity, calming the liver and extinguishing wind, and calming the mind and soothing the nerves. It not only effectively controls the nausea and vomiting symptoms caused by chemotherapy for intracranial tumors, but also harmonizes the body's Qi and organ functions. The Chinese medicine composition has a simple formula, widely available ingredients, and a simple preparation method; it is for topical application, convenient for clinical use, and has low adverse reactions.

To provide: means for suppressing a decrease in viscosity during long-term storage in a non-aqueous or low-water-content formulation for external application containing sofpironium bromide as an active ingredient; alternatively, a non-aqueous or low-water-content formulation of sofpironium bromide for external application in which a decrease in viscosity during long-term storage is suppressed, the sense of use for patients remains stable, and the formulation exhibits stable pharmaceutical properties; or alternatively, an external formulation of sofpironium bromide that exerts therapeutic effects on diseases involving acetylcholine (for example, primary focal hyperhidrosis).SOLUTION: A pharmaceutical formulation for external application to the human body surface in which a decrease in viscosity during long-term storage is suppressed contains sofpironium bromide, a water-soluble polymer, and ethanol, has a pH of 5.2 or less, and is a uniformly dispersed non-aqueous formulation or a low-water-content formulation having a water content of 5% or less.

The invention discloses an individualized infection control decision-making system based on wound surface microecology and a data processing method, the system collects a local sample of a wound surface, obtains a 16SrDNA or metagenome sequencing result, conventional etiology, inflammation indexes and patient conditions, and records plant defensin BKX-1 and antibacterial drug administration information; the micro-ecological and clinical features are subjected to fusion modeling based on machine learning, a wound infection severity score and a drug resistance risk score are output, an individualized infection control scheme is generated in combination with a preset antibacterial drug use rule, BKX-1 local drug use is preferentially recommended when the risk is low, broad-spectrum antibacterial drugs are reduced, and the risk is reduced. When the risk is high, etiology inspection and medication upgrading are prompted; and data of multiple patients can be counted to form quality indexes such as etiology inspection rate and the like. The method is beneficial to improving the etiology inspection rate, optimizing the use of antibacterial drugs and promoting wound infection control.

Topical pharmaceutical compositions comprising diethylene glycol monoethyl ether (DEGEE) maintained at an acidic pH. The pH of the formulation can be maintained at a pH of less than 6.3, or alternatively less than 6.0. Certain pharmaceutical composition further comprise an emulsifier blend of cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate, which is manufactured by Croda under the tradename Crodafos™ CES.

A nanoemulsion for topical drug delivery, comprising diclofenac alkali metal salt, diclofenac free acid, a solvent of the glycol, or glycol ether or glycol ether ester family, a nonionic surfactant with a hydrophilic lipophilic balance (HLB) value of about 14-16, caprylic capric triglyceride, and water. The nanoemulsion is useful in the treatment of joint pain, osteoarthritis, muscle pain, back pain and / or inflammation.

The use of compositions in solid anhydrous form and in the form of a film, which can be reconstituted into semi-solid form at the time of topical application, as well as delivery systems for active ingredients or drugs, the related pharmaceutical compositions, the method for obtaining them and their use are described.

A system and method of applying therapy to a patient includes navigating a dual lumen catheter to a desired segment of bronchus; inflating, via a first tube of the dual lumen catheter, a balloon located on a distal portion of the catheter to isolate the segment bronchial tube; injecting a therapeutic medium into the isolated segment bronchial tube via a second tube of the dual lumen catheter; and retracting the dual lumen catheter to leave the balloon indwelling, where the balloon retains the injected therapeutic medium in the isolated segment bronchial tube.

The present invention belongs to the field of polymer local drug delivery materials, and specifically relates to a polylactic acid fiber composite carrier for drug delivery, a preparation method and an application. A preparation method of a polylactic acid fiber composite carrier for drug delivery, S1: dissolving a polylactic acid-glycolic acid copolymer in a mixed solvent to obtain a polylactic acid-glycolic acid solution, using the polylactic acid-glycolic acid solution as an external phase and a glycerol aqueous solution as an internal phase, and coaxial electrospinning to obtain polylactic acid-glycolic acid fibers; S2: mixing the polylactic acid-glycolic acid fibers obtained in S1 with a quaternized chitosan solution to obtain a mixed solution, adding a sodium carbonate solution to the mixed solution for cross-linking, and obtaining a polylactic acid-glycolic acid fiber gel composite carrier. The carrier provided by the present invention can be applied to intracranial drug delivery, and can achieve a sequential slow release of drugs to achieve the purpose of long-term administration.

Disclosed herein are topical pharmaceutical compositions including an effective amount of trolamine salicylate that provide quick and long-lasting pain relief. Disclosed herein are also methods of treating a topical injury or pain with the topical pharmaceutical compositions.

The present invention provides a topical pharmaceutical composition that contains a nonsteroidal anti-inflammatory drug, a lower alcohol, vitamin E derivatives, and water, without the harmful effects caused by high concentrations of alcohol, and without suppressing the precipitation of insoluble substances. [Solution] The topical pharmaceutical composition of the present invention contains (A) a nonsteroidal anti-inflammatory drug, (B) a nonionic surfactant with an HLB value greater than 6.5, (C) 30-45% by weight of a lower alcohol, (D) an antihistamine, (E) 0.1-2% by weight of vitamin E derivatives, (F) 3-6% by weight of monoterpenes, and (G) water.

The invention relates to an external medicine for treating atopic dermatitis of infants, which is composed of active ingredients and medically acceptable auxiliary materials, and is characterized in that the active ingredients are prepared from the following raw material medicines in percentage by weight: 18.8-22.9% of perfoliote knotweed herb, 10.0-12.2% of Chinese arborvitae twig and leaf, 6.3-7.6% of folium artemisiae argyi, 12.5-15.3% of rhizoma polygonati, 10.0-12.2% of giant knotweed rhizome, 10.0-12.2% of cortex lycii radicis, 6.3-7.6% of peach kernel and 10.0-12.2% of fineleaf schizonepeta herb, and 6.3-7.6% of licorice root. The external medicine has a remarkable effect on treating atopic dermatitis of infants.

The present invention relates to multiple polypeptides with high safety, cell repair capacity, and anti-inflammatory, hydrating and moisturizing effects, and the use thereof in cosmetics, wherein the amino acid sequences of the polypeptides are as set forth in SEQ ID NO: 1-SEQ ID NO: 6. The present invention also relates to a polynucleotide encoding the polypeptides, wherein the sequence of the polynucleotide is as set forth in SEQ ID NO: 7-SEQ ID NO: 12, and the sequence of the polynucleotide can be used for the detection of Deinococcus weizhi. In addition, further provided is a topical drug or a cosmetic, which contains any one of the polypeptides or a combination thereof as an active ingredient.

The purpose of the present invention is to develop a novel method for treating diseases leading to severe corneal and conjunctival epithelial disorder from dysfunction of corneal / conjunctival epithelial stem cells, such as severe ocular surface diseases caused by chronic graft-versus-host disease.　The present invention provides a prophylactic or therapeutic agent for severe ocular surface disease for topical administration, the agent containing apocynin as an active ingredient.

The present application provides methods of treating a cancer in an individual that involves administering to the individual an agent that inhibits a tyrosine kinase or SHP-1 signaling ("TK / SHP-1 inhibitor") to the individual, wherein the agent is administered locally (i.e., topically). Also provided herein are topical drug delivery systems comprising the TK / SHP-1 inhibitor. In some cases, the methods involve administering the topical drug delivery system.